CSL to boost Hizentra capacity in bid for market share

Patient convenience is a key strategy for drugmakers looking to boost sales: Think Novartis' ($NVS) newly approved multiple sclerosis treatment Gilenya, for example; as a pill rather than an injected drug, analysts say, it stands to steal patients away from established, but less convenient drugs. Or think of the race to develop a diabetes drug that lasts a week or longer.

As Bloomberg reports, the convenience factor is playing out in the market for immunoglobulins, drugs for people born without the ability to make enough antibodies. Australia-based CSL is trying to woo patients away from doctor's-office infusions of drugs such as Baxter's ($BAX) Gammagard with its new Hizentra, which patients can inject themselves. And Hizentra has an advantage over potential home-infused competitors, because it's highly concentrated, so an infusion takes less time, analysts say. 

Doctors and analysts are expecting a big shift of patients to Hizentra, Bloomberg says, which gives CSL the chance to bypass Baxter, the leader in the $5 billion market for antibody-boosting drugs. Right now, CSL boasts 29 percent of that market, while Baxter has 33 percent. One thing that's been holding CSL back is production capacity; Hizentra is now made at a plant in Bern, Switzerland, that's running a full capacity, but the company is looking to FDA approval next year for Hizentra production at another plant nearby, allowing it to quadruple capacity.

 - read the Bloomberg story

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.